Table 2.
Univariate and multivariate Cox analysis for factors independently associated with PFS.
| Variables | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | p | aHR (95% CI) | p | ||
| AFP (ng/mL) | ≤7.5 | Ref | - | Ref | - |
| >7.5 | 2.52 (1.37–4.66) | 0.003 | 4.31 (1.66–11.20) | 0.003 | |
| miR-21 ratio (2−ΔΔCt) | ≤1.64 | Ref | - | Ref | - |
| >1.64 | 4.95 (1.93–12.65) | 0.001 | 8.61 (2.03–36.47) | 0.003 | |
| miR-122 (2−ΔΔCt) | ≤10.22 | Ref | - | Ref | - |
| >10.22 | 2.98 (1.10–8.09) | 0.03 | 2.11 (0.46–9.78) | 0.3 | |
| Radiological response | CR/PR | Ref | - | Ref | - |
| SD/PD | 6.37 (2.91–13.95) | <0.0001 | 10.44 (2.74–39.79) | 0.001 | |
| Number of nodules | ≤3 | Ref | - | Ref | - |
| >3 | 2.30 (1.24–4.25) | 0.008 | 0.51 (0.12–2.16) | 0.4 | |
| Diameter (cm) | ≤5 | Ref | - | Ref | - |
| >5 | 2.23 (0.97–5.16) | 0.06 | 1.78 (0.47–6.78) | 0.4 | |
| CRPH | No | Ref | - | Ref | - |
| Yes | 1.71 (0.92–3.17) | 0.09 | 0.56 (0.23–1.35) | 0.2 | |
| BCLC stage | 0/A | Ref | - | Ref | - |
| B/C | 2.54 (1.36–4.74) | 0.003 | 3.50 (0.77–15.96) | 0.1 | |
Abbreviations: HR, hazard ratio; CI; confidence interval; aHR, adjusted hazard ratio; Ref, reference; AFP, alpha-fetoprotein; CR, complete response, PR, partial response; SD, stable disease, PD, progressive disease; CRPH, clinically relevant portal hypertension; BCLC, Barcelona Clinic Liver Cancer.